Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

International Clinical Psychopharmacology

Volumn 15, Issue 1, 2000, Pages 57-60

  Vesely, C ^a   Kufferle B ^a   Brucke T ^a   Kasper, S ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b University Hospital for Neurology ^*

Author keywords

Quetiapine; Schizophrenia; Tardive dyskinesia

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; QUETIAPINE;

ADULT; ARTICLE; CASE REPORT; HUMAN; MALE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REMISSION; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0033954666     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015010-00010     Document Type: Article

References (28)

1. American Psychiatric Association (1994) DSM-IV: diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Borison RL, Arvanitis LA, Miller BG, Link CGG, Hong WW (1995) Seroquel (ICI 204 636): a novel atypical antipsychotic. Biol Psychiatry 37:661.
3. Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B et al. (1991) Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cerebral Blood Flow Metabol 11:220-228.
4. Brücke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S (1992) Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 339:497.
5. Casey DE (1987) Tardive dyskinesia. In: Psychopharmacology: the third generation of progress (Meltzer H, ed.), New York: Raven Press, pp. 1411-1419.
6. Casey DE (1995) Tardive Dyskinesia. In: Schizophrenia (Hirsch SR, Weinberger DR, eds), New York: Blackwell Science, pp. 553-565.
7. Casey DE, Gerlach J (1986) Tardive dyskinesia: what is the long term outcome? In: Tardive dyskinesia and neuroleptics: from dogma to reason (Casey DE, Gardos G, eds), Washington, DC: American Psychiatric Association, pp. 76-97.
8. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49(7): 538-544.
9. Gardos G, Cole JO, Salomon M, Schniebolk S (1987) Clinical forms of severe tardive dyskinesia. Am J Psychiatry 144:895-902.
10. Gardos G, Cole JO, Haskell D, Marby D, Paine SS, Moore P (1988) The natural history of tardive dyskinesia. J Clin Psychopharmacol 8 (Suppl. 4):31-33.
11. Guy W (1976) ECDEU Assessment manual for psychopharmacology - revised, Washington, DC: United States Government Printing Office, pp. 534-537.
12. Harasko-Van Der Meer C, Brücke T, Wenger S, Fischer P, Deecke L, Podreka I (1993) Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm 94:217-221.
13. Jeste DV, Wyatt RJ (1982) Therapeutic strategies against tardive dyskinesia. Arch Gen Psychiatry 39:803-816.
14. Kane JM, Liebermann JA (1992) Tardive dyskinesia. In: Adverse effects of psychotropic drugs (Kane JM, Liebermann JA), New York: The Guilford Press, pp. 235-245.
15. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Symptom Scale (PANSS) for Schizophrenia. Schizophr Bull 13:261-276.
16. Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, et al. (1996) (123 I) IBZM-SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 153:183-190.
17. Küfferle B, Brücke T, Topitz-Schratzberger A, Tauscher J, Grossler R, Vesely C, et al. (1996) Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Res 68:23-30.
18. Küfferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brucke T, Kasper S (1997) IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 133:323-328.
19. Liebermann JA, Saltz BL, Johns CA, Pollack S, Kane JM (1989) Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 25:57-62.
20. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical drugs on the basis of dopamine D-1, D-2 and serotonine pK1 values. J Pharmacol Exp Therapeut 25:238-246.
21. Migler BM, Warawa EJ, Malick JB (1993) Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 112:299-307.
22. Nyberg S, Farde L, Erikson L, Halldin C, Eriksson B (1993) 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology 110:265-272.
23. Saller CF, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292.
24. Schooler NR, Kane JM (1982) Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
25. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19.
26. Tarsy D, Baldessarini RJ (1973) Pharmacologically induced behavioural supersensitivity to apomorphine. Nature 245:262-263.
27. Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O (1995) Seroquel (ICI 204 636), a putative 'atypical' antipsychotic, in schizophrenia with positive symtomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119:231-238.
28. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.